HALETHORPE, Md.--(BUSINESS WIRE)--Cureveda LLC, a company focused on the development of therapeutics to treat inflammatory and fibrotic diseases, announced today that it has been awarded two Phase I Small Business Technology Transfer (STTR) grants totaling $450,000 from the National Institutes of Health (NIH). These grants will support preclinical studies to test the efficacy of VEDA-1209 as a novel treatment for systemic sclerosis and chronic obstructive pulmonary disease (COPD). Current treatments for both these diseases focus primarily on symptom relief but do not target the underlying disease processes. VEDA-1209 activates Nrf2, the master regulator of anti-oxidant pathways in the cell, resulting in inhibition of the fibrotic and inflammatory processes that drive systemic sclerosis and COPD, respectively.
Help employers find you! Check out all the jobs and post your resume.
Help employers find you! Check out all the jobs and post your resume.
